Multiple Myeloma Articles

Frontline Daratumumab Triplet Approved in EU for Transplant-Ineligible Myeloma
The European Commission has approved the triplet regimen of daratumumab with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
New Myeloma Guidelines Reflect Advances in Imaging, Explosion of Treatment Options
Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.
Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.
Anti-BCMA Approaches Ascending in Multiple Myeloma
Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.
FDA Grants RMAT Designation to CAR T-Cell Therapy CT053 for Myeloma
The FDA has granted a Regenerative Medicine Advanced Therapy designation to the investigational anti-BCMA CAR T-cell therapy CT053 for the treatment of patients with relapsed/refractory multiple myeloma.
Daratumumab Triplet Nears EU Approval for Frontline Transplant-Ineligible Myeloma
The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of daratumumab for use in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Myeloma Regimens Require Coping Mechanisms for Toxicity
Adam J. Waxman, MD, MS, discusses new and upcoming multiple myeloma treatments and how to optimally manage toxicities from these regimens. 
Expert Sheds Light on Rapid Progress in Relapsed/Refractory Myeloma
Ivan M. Borrello, MD, discusses the most impactful agents that have entered the relapsed/refractory setting of multiple myeloma and details some of the guiding principles of treatment selection.
FDA Approves Frontline Daratumumab Regimen for Transplant-Eligible Myeloma
The FDA has approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Selinexor Improves Late-Stage Treatment Options for Multiple Myeloma
Sundar Jagannath, MBBS, discusses the significance the selinexor (Xpovio) approval has for patients with myeloma, the tolerability of the agent, and the management of related adverse events.
Publication Bottom Border
Border Publication
x